Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to Buy at Wall Street Zen

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Friday.

Separately, Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Monday, April 28th.

Bayer Aktiengesellschaft Trading Up 0.9%

Shares of Bayer Aktiengesellschaft stock opened at $7.59 on Friday. The firm has a market capitalization of $29.83 billion, a PE ratio of -29.19 and a beta of 0.85. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.58. The firm’s 50-day moving average price is $6.45 and its 200 day moving average price is $5.87. The company has a current ratio of 1.32, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. On average, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.